NL-OMON21758尚未招募不适用
Phase 0 proof of concept study: a clinical pharmacokinetic microdosing trial with gemcitabine
Antoni van Leeuwenhoek hospital0 个研究点目标入组 10 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 10
研究概览
简要总结
one
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Age > 18 years.
- •2.Indication for treatment with gemcitabine.
排除标准
- •Subjects will not be eligible for study entry if any of the following criteria are met:
- •1.Prior chemotherapy, radiotherapy, radio immunotherapy, or immunotherapy within 7 days of the first dose of study treatment
研究者
相似试验
已完成
不适用
Phase 0 proof of concept study: a clinical pharmacokinetic microdosing trial with gemcitabinemetastatic bladder cancer and malignant mesotheliomaMetastatic non-small cell lung cancer10027655NL-OMON45398Antoni van Leeuwenhoek Ziekenhuis10
已完成
不适用
A Study of Cediranib and Olaparib at Disease Worsening in Ovarian CancerOvarian CancerNCT02681237University Health Network, Toronto34
已完成
2 期
Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to RavulizumabParoxysmal Nocturnal HemoglobinuriaNCT05972967Omeros Corporation12
已完成
Unknown
Studying the safety and the pharmacokinetics after single dosing of KDF2001 in healthy adultEndocrine, nutritional and metabolic diseasesKCT0009163Kyung Dong Pharmaceutical40
已完成
1 期
Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal HemoglobinuriaNCT05889299Omeros Corporation15